Kaleido Biosciences Ownership

KLDODelisted Stock  USD 0.01  0.00  0.00%   
Kaleido Biosciences maintains a total of 42.62 Million outstanding shares. Roughly 98.91 % of Kaleido Biosciences outstanding shares are held by general public with 0.73 pct. owned by insiders and only 0.36 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Kaleido Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Kaleido Biosciences, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Kaleido Pink Sheet Ownership Analysis

The company has price-to-book ratio of 0.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kaleido Biosciences recorded a loss per share of 2.16. The entity had not issued any dividends in recent years. Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 76 people.The quote for Kaleido Biosciences is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Kaleido Biosciences contact the company at 617 674 9000 or learn more at https://kaleido.com.

Kaleido Biosciences Outstanding Bonds

Kaleido Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kaleido Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kaleido bonds can be classified according to their maturity, which is the date when Kaleido Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in Kaleido Pink Sheet

If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges